|
English
|
正體中文
|
简体中文
|
總筆數 :2817890
|
|
造訪人次 :
27950372
線上人數 :
351
教育部委託研究計畫 計畫執行:國立臺灣大學圖書館
|
|
|
"ichikawa k"的相關文件
顯示項目 1-5 / 5 (共1頁)
1
每頁顯示[10|25|50]項目
| 臺大學術典藏 |
2021-09-01T01:54:02Z |
Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3
|
Chen K.-F.; Chen H.-L.; Liu C.-Y.; Tai W.-T.; Ichikawa K.; Chen P.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:51Z |
Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody
|
Chen K.-F.; Chen H.-L.; Shiau C.-W.; Liu C.-Y.; Chu P.-Y.; Tai W.-T.; Ichikawa K.; Chen P.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-07-03T03:34:26Z |
Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3
|
Chen K.-F.; Chen H.-L.; Liu C.-Y.; Tai W.-T.; Ichikawa K.; PEI-JER CHEN; Cheng A.-L. |
| 臺大學術典藏 |
2021-07-03T03:34:22Z |
Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody
|
Chen K.-F.; Chen H.-L.; Shiau C.-W.; Liu C.-Y.; Chu P.-Y.; Tai W.-T.; Ichikawa K.; PEI-JER CHEN; Cheng A.-L. |
| 臺大學術典藏 |
2018-09-10T09:39:54Z |
Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody
|
Chen, K.-F.;Chen, H.-L.;Shiau, C.-W.;Liu, C.-Y.;Chu, P.-Y.;Tai, W.-T.;Ichikawa, K.;Chen, P.-J.;Cheng, A.-L.; PEI-JER CHEN; Kuen-Feng Chen; ANN-LII CHENG |
顯示項目 1-5 / 5 (共1頁)
1
每頁顯示[10|25|50]項目
|
